Leniolisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.604
CATDS
0.017
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Leniolisib. Strongest target: AKT3 at 27.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | AKT3 | 27.4% | 72.6% |
| 2 | DAPK2 | 20.1% | 79.9% |
| 3 | SYK | 19.5% | 80.5% |
| 4 | STK33 | 19.2% | 80.8% |
| 5 | ALK4_ACVR1B | 18.6% | 81.4% |
| 6 | MAST3 | 18.0% | 82.0% |
| 7 | MEKK3 | 17.2% | 82.8% |
| 8 | WNK3 | 17.0% | 83.0% |
| 9 | CDC7_DBF4 | 15.8% | 84.2% |
| 10 | ERK1 | 15.8% | 84.2% |
| 11 | CDK1_CYCLIN_A | 15.7% | 84.3% |
| 12 | PDK3_PDHK3 | 15.7% | 84.3% |
| 13 | DNA_PK | 15.6% | 84.4% |
| 14 | EPHA6 | 15.3% | 84.7% |
| 15 | TYRO3_SKY | 15.2% | 84.8% |
| 16 | RAF1 | 15.2% | 84.8% |
| 17 | CDK6_CYCLIN_D3 | 14.3% | 85.7% |
| 18 | JNK2 | 13.5% | 86.5% |
| 19 | ERN1_IRE1 | 13.4% | 86.6% |
| 20 | PKG1B | 13.4% | 86.6% |
Selectivity landscape
Where Leniolisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Leniolisib.
Atlas insights for Leniolisib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 418.57 | |
| ALLOGRAFT_REJECTION | 921.08 | |
| ANDROGEN_RESPONSE | 386.74 | |
| ANGIOGENESIS | 123.26 | |
| APICAL_JUNCTION | 1098.71 | |
| APICAL_SURFACE | 154.03 | |
| APOPTOSIS | 1311.72 | |
| BILE_ACID_METABOLISM | 141.60 | |
| CHOLESTEROL_HOMEOSTASIS | 130.73 | |
| COAGULATION | 171.81 | |
| COMPLEMENT | 647.69 | |
| DNA_REPAIR | 266.95 | |
| E2F_TARGETS | 1194.23 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 411.46 | |
| ESTROGEN_RESPONSE_EARLY | 684.40 | |
| ESTROGEN_RESPONSE_LATE | 572.22 | |
| FATTY_ACID_METABOLISM | 94.57 | |
| G2M_CHECKPOINT | 1039.45 | |
| GLYCOLYSIS | 526.28 | |
| HEDGEHOG_SIGNALING | 94.89 | |
| HEME_METABOLISM | 460.58 | |
| HYPOXIA | 806.25 | |
| IL2_STAT5_SIGNALING | 464.42 | |
| IL6_JAK_STAT3_SIGNALING | 651.39 | |
| INFLAMMATORY_RESPONSE | 788.75 | |
| INTERFERON_ALPHA_RESPONSE | 146.51 | |
| INTERFERON_GAMMA_RESPONSE | 831.57 | |
| KRAS_SIGNALING_DN | 228.81 | |
| KRAS_SIGNALING_UP | 390.19 | |
| MITOTIC_SPINDLE | 958.49 | |
| MTORC1_SIGNALING | 688.23 | |
| MYC_TARGETS_V1 | 773.64 | |
| MYC_TARGETS_V2 | 252.18 | |
| MYOGENESIS | 655.83 | |
| NOTCH_SIGNALING | 96.02 | |
| OXIDATIVE_PHOSPHORYLATION | 188.92 | |
| P53_PATHWAY | 712.95 | |
| PANCREAS_BETA_CELLS | 106.00 | |
| PEROXISOME | 178.46 | |
| PI3K_AKT_MTOR_SIGNALING | 1468.65 | |
| PROTEIN_SECRETION | 258.86 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 65.07 | |
| SPERMATOGENESIS | 460.64 | |
| TGF_BETA_SIGNALING | 381.55 | |
| TNFA_SIGNALING_VIA_NFKB | 933.94 | |
| UNFOLDED_PROTEIN_RESPONSE | 346.37 | |
| UV_RESPONSE_DN | 738.21 | |
| UV_RESPONSE_UP | 560.15 | |
| WNT_BETA_CATENIN_SIGNALING | 425.91 | |
| XENOBIOTIC_METABOLISM | 316.67 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.868 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.851 |
| SRR1443713 | GTEX | 0.834 |
| SRR12202498 | — | 0.833 |
| R247 | — | 0.833 |
Annotations
Sign in to read and post annotations.
Loading…